This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imai, H. Articles by Tan, E. M. Search for Related Content PubMed PubMed Citation Articles by Imai, H. Articles by Tan, E. M.

American Journal of Pathology, Vol 140, 859-870, Copyright © 1992 by American Society for Investigative Pathology

REGULAR ARTICLES

Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies

H Imai, RL Ochs, K Kiyosawa, S Furuta, RM Nakamura and EM Tan
W.M. Keck Autoimmune Disease Center, Scripps Research Institute, La Jolla, California 92037.

Patients with hepatocellular carcinoma (HCC), gastrointestinal, lung, and ovarian cancers were shown to have autoantibodies to nuclear and nucleolar antigens as detected by immunofluorescence on cell substrates. The frequency of antinuclear antibodies (ANAs) was significantly higher (P less than 0.001) in patients with HCC (57/184 = 31%) than in patients with chronic hepatitis or liver cirrhosis (25/187 = 13%). Although a range of fluorescence patterns was observed, a higher percentage of nucleolar fluorescence was detected in HCC, and three of these nucleolar antigens were identified. They were NOR-90, nucleolus organizer region doublet polypeptides of 93 and 89 kDa involved in RNA polymerase I transcription; fibrillarin, a 34 kDa protein of the nucleolar U3 ribonucleoprotein particle which is engaged in preribosomal RNA processing; and nucleophosmin/protein B23, a 37 kDa polypeptide which is associated with ribosome maturation and cellular proliferation. All these antigens are nucleolar components that are engaged in some aspect of ribosome biosynthesis. Since autoantibodies to these nucleolar antigens have also been found in systemic autoimmune diseases, they do not represent autoimmune reactions unique to cancer but might reflect reaction pathways related to immune responses that are antigen-driven. The ANA response in HCC appears to be dynamic reactions to this antigen-drive since some patients with chronic liver disease showed seroconversion to ANA positivity, marked increase in titer and/or change in antibody specificity preceding or coincident with clinical detection of HCC. These changes in ANA showed a close temporal relationship with transformation from long-established chronic liver disease to HCC.

This article has been cited by other articles:

				T. Sittler, J. Zhou, J. Park, N. K. Yuen, S. Sarantopoulos, J. Mollick, R. Salgia, A. Giobbie-Hurder, G. Dranoff, and F. S. Hodi Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity Clin. Cancer Res., June 15, 2008; 14(12): 3896 - 3905. [Abstract] [Full Text] [PDF]

				S Khan, A Alvi, S Holding, M L Kemp, D Raine, P C Dore, and W A C Sewell The clinical significance of antinucleolar antibodies J. Clin. Pathol., March 1, 2008; 61(3): 283 - 286. [Abstract] [Full Text] [PDF]

				D. B. Ulanet, M. Torbenson, C. V. Dang, L. Casciola-Rosen, and A. Rosen Unique conformation of cancer autoantigen B23 in hepatoma: A mechanism for specificity in the autoimmune response PNAS, October 14, 2003; 100(21): 12361 - 12366. [Abstract] [Full Text] [PDF]

				J.-Y. Zhang, C. A. Casiano, X.-X. Peng, J. A. Koziol, E. K. L. Chan, and E. M. Tan Enhancement of Antibody Detection in Cancer Using Panel of Recombinant Tumor-associated Antigens Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 136 - 143. [Abstract] [Full Text] [PDF]

				F. Le Naour, F. Brichory, D. E. Misek, C. Brechot, S. M. Hanash, and L. Beretta A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis Mol. Cell. Proteomics, March 1, 2002; 1(3): 197 - 203. [Abstract] [Full Text] [PDF]

				M Abu-Shakra, D Buskila, M Ehrenfeld, K Conrad, and Y Shoenfeld Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies Ann Rheum Dis, May 1, 2001; 60(5): 433 - 441. [Abstract] [Full Text] [PDF]

				F. Fernandez-Madrid, P. J. VandeVord, X. Yang, R. L. Karvonen, P. M. Simpson, M. J. Kraut, J. L. Granda, and J. E. Tomkiel Antinuclear Antibodies as Potential Markers of Lung Cancer Clin. Cancer Res., June 1, 1999; 5(6): 1393 - 1400. [Abstract] [Full Text] [PDF]

				A. Melnick and J. D. Licht Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood, May 15, 1999; 93(10): 3167 - 3215. [Full Text] [PDF]

				J.-Y. Zhang, E. K.L. Chan, X.-X. Peng, and E. M. Tan A Novel Cytoplasmic Protein with RNA-binding Motifs Is an Autoantigen in Human Hepatocellular Carcinoma J. Exp. Med., April 5, 1999; 189(7): 1101 - 1110. [Abstract] [Full Text] [PDF]